Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock, $0.00001 par value
-
Shares outstanding
-
120,020,745
-
Total 13F shares
-
28,456,883
-
Share change
-
-3,663,878
-
Total reported value
-
$46,099,261
-
Price per share
-
$1.62
-
Number of holders
-
56
-
Value change
-
-$5,512,533
-
Number of buys
-
20
-
Number of sells
-
41
Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) as of Q2 2020
As of 30 Jun 2020,
Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) was held by
56 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
28,456,883 shares.
The largest 10 holders included
MFN Partners Management, LP, RENAISSANCE TECHNOLOGIES LLC, Samsara BioCapital, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., Sofinnova Investments, Inc., Endurant Capital Management LP, Parkman Healthcare Partners LLC, Vivo Capital, LLC, Rock Springs Capital Management LP, and EcoR1 Capital, LLC.
This page lists
56
institutional shareholders reporting positions in this security
for the Q2 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.